VIM0423 / Vima Therapeutics - LARVOL DELTA

Vista PD: A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Vima Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Vista PD: A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Vima Therapeutics

New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Vima tacks on $40M to series A, expands plans for lead programme into Parkinson's (Firstwordpharma Press Release) - "Vima plans to start a Phase II study of VIM0423 in Parkinson's disease mid-year..."

Financing • New P2 trial • Parkinson's Disease